Abeona Therapeutics (ABEO) closed at $2.46 on November 10, 2026, down 3.3% from the previous close, on volume of 3,508,109 shares (30-day average 1,456,258).
Data as of November 10, 2026.
10-Nov-2026
| # | Date | Strategy | Legs | Contracts |
|---|
Ranked by contracts: multi-leg trades of 200 or more contracts on one day, through Nov 9, 2026. See the 10 largest for 30, 60 and 90 days
Oppenheimer Sticks to Their Buy Rating for Abeona Therapeutics (ABEO)
TipRanks (Tue, 10-Nov 7:56 AM ET)
Abeona Therapeutics Announces Participation in Upcoming Investor Conferences
Globe Newswire (Tue, 10-Nov 7:30 AM ET)
Abeona Adds Phase 3-Ready ABO-801 for EoE With No Upfront Cash as It Lines Up $30 Million PIPE
Market Chameleon (Mon, 9-Nov 4:53 AM ET)
Abeona Therapeutics Acquires ABO-801 in Equity Financing
TipRanks (Mon, 9-Nov 7:00 AM ET)
Abeona Therapeutics Reports Q3 Progress, Acquires Phase 3-Ready Asset
TipRanks (Mon, 9-Nov 6:58 AM ET)
Abeona Therapeutics GAAP EPS of -$0.08 beats by $0.10, revenue of $13.49M misses by $1.33M
Seeking Alpha News (Mon, 9-Nov 6:39 AM ET)
Abeona Therapeutics Reports Third Quarter 2026 Financial Results and ZEVASKYN Commercial Progress
Globe Newswire (Mon, 9-Nov 6:35 AM ET)
Globe Newswire (Mon, 9-Nov 6:30 AM ET)
Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Globe Newswire (Mon, 2-Nov 7:46 AM ET)
Globe Newswire (Tue, 6-Oct 6:32 PM ET)
Abeona Therapeutics Inc is a commercial-stage biopharmaceutical company. The company is focused on developing cell and gene therapies for life-threatening diseases. The company's ZEVASKYN (prademagene zamikeracel) is an autologous cell-based gene therapy for the treatment of wounds in adults and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB). The company's development portfolio includes adeno-associated virus (AAV)-based gene therapies for ophthalmic diseases with high unmet medical need.
Abeona Therapeutics trades on the NASDAQ stock market under the symbol ABEO.
As of November 10, 2026, ABEO stock price declined to $2.45 with 3,508,109 million shares trading.
ABEO has a beta of 2.61, meaning it tends to be more sensitive to market movements. ABEO has a correlation of 0.38 to the broad based SPY ETF.
ABEO has a market cap of $151.38 million. This is considered a Micro Cap stock.
Last quarter Abeona Therapeutics reported $13 million in Revenue and -$.08 earnings per share. This fell short of revenue expectation by $-2 million and exceeded earnings estimates by $.08.
In the last 3 years, ABEO traded as high as $9.01 and as low as $2.30.
The top ETF exchange traded funds that ABEO belongs to (by Net Assets): VTI, IWM, VXF, VTWO, IWN.
ABEO has underperformed the market in the last year with a price return of -41.5% while the SPY ETF gained +12.9%. ABEO has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -66.1% and -43.0%, respectively, while the SPY returned -2.8% and -2.0%, respectively.
ABEO support price is $2.44 and resistance is $2.64 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ABEO shares will trade within this expected range on the day.
